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Background: Infective endocarditis is a life threatening complication of intravenous drug abuse, which continues
to be a major burden with inadequately characterised long-term outcomes. We reviewed our institutional experience
of surgical treatment of infective endocarditis in active intravenous drug abusers with the aim of identifying the
determinants long-term outcome of this distinct subgroup of infective endocarditis patients.
Methods: A total of 451 patients underwent surgery for infective endocarditis between January 1993 and July 2013 at
the University Hospital of Heidelberg. Of these patients, 20 (7 female, mean age 35 ± 7.7 years) underwent surgery for
infective endocarditis with a history of active intravenous drug abuse. Mean follow-up was 2504 ± 1842 days.
Results: Staphylococcus aureus was the most common pathogen detected in preoperative blood cultures. Two
patients (10%) died before postoperative day 30. Survival at 1, 5 and 10 years was 90%, 85% and 85%, respectively.
Freedom from reoperation was 100%. Higher NYHA functional class, higher EuroSCORE II, HIV infection, longer
operating time, postoperative fever and higher requirement for red blood cell transfusion were associated with 90-day
mortality.
Conclusions: In active intravenous drug abusers, surgical treatment for infective endocarditis should be performed as
extensively as possible and be followed by an aggressive postoperative antibiotic therapy to avoid high mortality. Early
surgical intervention is advisable in patients with precipitous cardiac deterioration and under conditions of staphylococcal
endocarditis. However, larger studies are necessary to confirm our preliminary results.
Keywords: Infective endocarditis, Intravenous drug abuse, Cardiac surgery, Heart valveBackground
Infective endocarditis (IE) is a serious clinical condition
with an annual incidence in the general population of
approximately 1.7 - 6.2 cases per 100,000 patients with a
mortality of 20-30% [1]. However, the incidence in intra-
venous drug users (IVDUs) is 2% to 5% and is respon-
sible for 5% to 10% of deaths in this exceptional patient
cohort [2]. IE in IVDUs differs substantially from that* Correspondence: weymann.alexander@googlemail.com
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article, unless otherwise stated.typically observed in the general population in terms of
microbiology, the involvement of multiple heart valves
and prognosis [3].
The diagnosis of IE is challenging and may lead to in-
creased mortality if the characteristic oslerian manifesta-
tions are absent, particularly among IVDU patients
infected with with S. aureus and HACEK (Haemophilus
species, Actinobacillus actinomycetemcomitans, Cardio-
bacterium hominis, Eikenella corrodens, Kingella kingae)
[4]. Polymicrobial endocarditis is a variant of IE, which
often occurs in IVDUs with a fatal outcome, especially
when Candida species, Bartonella spp. or Tropheryma
whipplei are involved [5]. Standard antibiotics are fre-
quently not particularly effective because these microor-
ganisms are attached in a protective biofilm form totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to antibiotics [3]. If valve destruction progresses and
the infectious constellation is no longer controllable,
early surgical treatment becomes mandatory. The sur-
geon generally faces a very sick patient, often suffering
from severe sepsis and congestive heart failure. In this
situation, the surgical rule not to implant prosthetic
material into infected tissue unavoidably has to be
broken and balanced against the risk of early reinfec-
tion [6]. Given the rare nature of the condition, there
are only a few studies or case reports dealing with this
topic.
The purpose of this study was to review our institu-
tional experience of IE in IVDUs, to identify predictive
factors influencing the perioperative risk, and to estab-
lish perioperative management strategies with the aim
of improving future clinical management and outcome.
Methods
Study design and patient cohort
From January 1993 to July 2013 a total of 451 patients
underwent surgery for IE at University Hospital Heidelberg.
Out of this cohort, 20 active IVDU patients were identi-
fied and included in the study. The study was approved
by the Ethics Committee, Medical Faculty University of
Heidelberg, application number S-198/2013. Patients
were only included in the study if the endocarditis was
considered to be “definite” according to the modified cri-
teria proposed by Duke [7,8] and there was documented
acknowledgement by the patient of active intravenous
drug abuse (heroin) until the day of admission. Addition-
ally, other drug use history was obtained including type
of drug (marijuana, cocaine, amphetamines, ecstasy and
methadone). Patient demographics, preoperative medical
history, intra-operative and post-operative course were
collected retrospectively from hospital medical records.
Valve-related complications were documented according
to the guidelines for reporting morbidity and mortality
after cardiac valvular surgery [9]. Transesophageal echo-
cardiography was performed in all survivors. Mortality
was determined using the bureau of vital statistics data-
base if such information was unobtainable from the med-
ical records.
The primary endpoint in the study cohort was sur-
vival at 90 days after surgical treatment in our institu-
tion. The secondary endpoints were perioperative
clinical characteristics and adverse events, which could
have an impact on early postoperative mortality. All
the patients completed a follow-up period of at least
90 days and were divided into two groups depending
on 90-day survival. The demographic and perioperative
variables of the 90-day survivors and non-survivors
were compared to identify the predictors of 90-day
overall mortality.Diagnostic methodology and indications for surgical
treatment
The diagnosis of IE was made using a combination of
clinical and laboratory findings and was confirmed by
transesophageal echocardiography in all patients accord-
ing to the modified Duke criteria. Mandatory preopera-
tive studies included abdominal ultrasound or computer
assisted tomography to rule out septic foci. Absolute in-
dications for surgical treatment during the active phase
of IE, according to our overall surgical principles at the
University Hospital of Heidelberg, included the follow-
ing: progressive cardiac failure, unmanageable infection
despite antibiotic therapy, recurrent embolic events,
acute renal failure and prosthetic valve endocarditis.
Each patient in our cohort met at least one of these
criteria.
Surgical technique
All patients underwent surgery with cardiopulmonary
bypass with mild hypothermia. Myocardial protection
was achieved with antegrade cold crystalloid cardiople-
gia. Tricuspid valve surgical procedures were performed
with occlusion of both caval veins while the heart was
beating or fibrillating.
Our treatment policy for IE is radical debridement of
infected tissue followed by generous irrigation with anti-
biotic solution. All infected or necrotic structures
surrounding the valves were resected irrespective of
whether the conduction system was damaged or large
defects in the myocardial or fibrous tissue were created.
The valvular annulus and adjacent structures were care-
fully examined with the aim of detecting extension of
the infective process. Abscesses were resected as com-
pletely as possible so as not to leave any macroscopically
infected tissue in situ. Large evacuated abscess cavities
were filled with gentamycin-fibrin glue. Ventricular sep-
tal defects caused by extension of abscess cavities were
closed with Dacron patches. Allografts were preferred
for aortic root reconstruction in cases of annular de-
struction and periannular invasion. If there was a re-
quirement to buttress the suture line of a prosthetic
valve, autologous pericardium was the material of
choice. Defects were subsequently closed with pericar-
dial patches or if possible, by direct suturing. Generally,
the use of foreign material was kept to a minimum.
If the valves had to be replaced, the type of valve im-
planted was generally determined by the preference of
the surgeon. Prostheses, patch material, and sutures
were soaked in gentamicin solution before implantation.
Postoperative care
In addition to hemodynamic stabilization, an import-
ant goal of postoperative intensive therapy was to
control the local and systemic infective process. In
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against the infecting microorganisms. In the presence
of methicillin-resistant staphylococci, vancomycin was
used in combination with tobramycin or rifampicin.
Methicillin-susceptible staphylococci were treated with
a semisynthetic penicillinase-resistant penicillin and ri-
fampicin. If no rapid disappearance of infective signs
could be achieved, the therapy was changed to vanco-
mycin alone or in combination. If no microorganisms
could be isolated, broad spectrum antibiotic therapy
with imipenem and vancomycin or teicoplanin was
used. In each case, intravenous antibiotic therapy was
maintained for 6 weeks postoperatively.
Post-operative transesophageal echocardiography was
performed regularly to exclude recurrent vegetations or
paravalvular leaks. These findings in combination with
evidence of persisting infection would give a strong sus-
picion of ongoing or recurrent endocarditis and per se
would justify re-operation.
Statistical analysis
Data are presented as continuous or categorical vari-
ables. Continuous data were evaluated for normality
using the one sample Kolmogorov-Smirnov test. As all
continuous variables were normally distributed, they
were analyzed with the Student t-test and expressed as
the mean ± standard deviation. Pearson’s χ2 or Fisher
exact tests were used for categorical data dependent on
the minimum expected count in each cross tab. The cat-
egorical data are expressed as total numbers and per-
centages. The ANOVA with repeated measurements was
applied for the comparison of survivors and non-
survivors regarding perioperative inflammatory markers.
Kaplan-Meier actuarial survival estimate was generated
to analyse survival of the entire cohort. Multivariate lo-
gistic regression analysis was performed on univariate
predictors for 90-days mortality with an entry criterion
of p < 0.05. All data were analyzed using the Statistical




The mean age of the entire population was 35 ± 7.7 years
and 35% (n = 7) of the population were female. All pa-
tients in the study cohort were active IVDUs and had
advanced heart failure with the mean NYHA stage of
3.4 ± 0.9. One patient from the cohort had previous aor-
tic valve endocarditis and had undergone a previous aor-
tic valve replacement. Further past medical history
included active Hepatitis B (70.6%, n = 12), renal insuffi-
ciency (35%, n = 7), insulin dependent diabetes mellitus
(5%, n = 1) and history of cerebrovascular event (5%, n = 1).
The mean duration of i.v. drug abuse was 15.2 ± 10.6 years.The affected valves were aortic (20%, n = 4), mitral (10%,
n = 2), tricuspid (40%, n = 8), combined aortic and mitral
(10%, n = 2), combined aortic and tricuspid (5%, n = 1),
combined mitral and tricuspid (10%, n = 2) and combined
aortic, mitral and pulmonary (5%, n = 1) valves. Eighty per
cent of the cohort (n = 16) had positive blood cultures and
85% (n = 17) had valve vegetations confirmed by trans-
esophageal echocardiography. The mean size of the valve
vegetations was 25 ± 9.4 mm. The surgery was performed
through a median sternotomy using cardiopulmonary by-
pass (CPB) with a mean CPB time of 139 ± 78 min and
cross clamp time of 92 ± 49 min. In cases of valve replace-
ment, mechanical or biological prostheses were used in
55% (n = 11) and 40% (n = 8), respectively. In five percent
of cases (n = 1) the valve was reconstructed. Moreover,
one patient with severe aortic valve/root destruction had
several abscess cavities including periannular invasion
that were filled with gentamycin-fibrin glue and subse-
quently closed with pericardial patches. After that an
allograft was anchored in the reconstructed aortic root.
The other patient with extensive, infiltrative aortic and
tricuspid valve endocarditis needed closure of a ventricu-
lar septal defect with a Dacron patch caused by extension
of abscess cavities. Large parts of the walls of the atria
and the right ventricle were destroyed by the infection,
so that additional reconstruction with Dacron patches
had to be performed. In 12 patients splenectomy was
performed simultaneously for severe abscess formation,
which was diagnosed preoperatively.
Thirty five per cent of cases (n = 7) were urgent, 60%
(n = 12) were emergent and one case was performed as a
salvage procedure. Perioperatively, patients received
1440 ± 991 mL of red blood cells, 410 ± 428 mL of fresh
frozen plasma and 287 ± 330 mL of platelets. The mean
operation duration was 236 ± 96 min. Postoperatively, all
patients were transferred to the intensive care unit
(mean stay 3.9 ± 3.1 days). Having achieved hemodynamic
stability and after extubation, the patients were transferred
to the high dependency unit (mean stay 12.6 ± 14 days)
before they were discharged to normal surgical ward.
The mean follow-up was 2504 ± 1842 days. The overall
survival of the patient cohort was 90% at one year, and
remained at 85% from 3 years to the end of follow-up
(Figure 1). Seventeen patients survived until the end of
follow-up, whereas 3 patients died at post-operative day
6, 8 and 591 days. The cause of death was severe sepsis
in the first two cases and sudden cardiac death in the
third. Eleven patients experienced recurrent IE during
follow-up and were managed with i.v. antibiotics without
the need for surgery. The most common postoperative
adverse events were atrial fibrillation in 65% (n = 13),
atrioventricular block in 25% (n = 5) with the need for
permanent pacemaker implantation in 10% (n = 2), renal
failure in 35% (n = 7), coagulation disorder (disseminated
Figure 1 Kaplan-Meier survival estimate for IVDU patients with IE who underwent surgical treatment between January 1993 and
July 2013.
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vascular event (ischemic stroke) in 5% (n = 1). No myo-
cardial infarction or deep sternal infections occurred
postoperatively in the study cohort.
Staphylococcus aureus was the pathogen most com-
monly identified from blood cultures accounting for 40%
(n = 8) of infections, followed by Enterococcus spec. 10%
(n = 2), coagulase negative staphylococci 10% (n = 2) and
streptococci 20% (n = 4). 20% (n = 4) of patients were
culture-negative. The mean follow-up for the entire co-
hort was 2504 ± 1842 days. No patients were lost to
follow-up.
Univariate and multivariate predictors of early mortality
A subgroup analysis of 90-day survivors and non-
survivors is presented in Tables 1 and 2. There were no
statistically significant differences with respect to pre-
operative demographics and most clinical baseline char-
acteristics including patients’ preoperative blood culture
profile. However, non-survivors had significantly higher
EuroSCORE II (p = 0.036), higher NYHA class (p = 0.005)
and a significantly higher rate of HIV infection (p = 0.047).
Also, non-survivors had a significantly longer operating
time (p = 0.016) and higher RBC transfusion requirement
(p = 0.020). Figures 2, 3, and 4 show the postoperative pro-
file of white cell count (WCC), CRP and body temperature
reflecting patients’ perioperative inflammatory status. In
this respect, 90-day non-survivors had significantly higher
body temperature over the first week postoperatively com-
pared to 90-day survivors, while there were no significantdifferences regarding WCC and CRP levels. However,
none of the univariate predictors reached statistical signifi-
cance in multivariate logistic regression analysis.
Discussion
The management of IE in active IVDUs remains challen-
ging and has a high operative mortality. Often the sur-
geon faces a very sick patient with septic complications,
which need to be treated surgically as soon as possible
after failed antibiotic therapy. This report summarizes
our institutional experience of this high-risk group
treated surgically over a 20-year period. We critically
analysed our surgical treatment of IVDUs, in particular
the causative pathogens with the aim of identifying
methods, which can improve the outcome of this sub-
group of patients.
Ninety percent of our patients survived to hospital dis-
charge, a survival rate that is comparable with reports of
other institutions [10-12]. The fact that 35% of the cases
were urgent, 60% were emergent and one case was a sal-
vage procedure reflects the severe stage of the disease in
our cohort. Nevertheless, we were able to achieve a
long-term survival of 85%.
Staphylococcus aureus was the most common pathogen
isolated in our patient group but was not associated with
significantly decreased 90-day survival when compared
with the other pathogens. In contrast, other investigators
have reported that Staphylococcus aureus - associated IE
was identified as the most common cause of IE and is
an independent predictor of mortality [13,14]. For this






Age (yrs) 35.1 ± 7.7 34.5 ± 10.6 0.926
Female 6 (33.3%) 1 (50%) 0.639
BMI 23.8 ± 4.7 23.1 ± 0.42 0.851
Diabetes mellitus 1 (5.6%) 0 0.732
NYHA stage 3.28 ± 0.9 4.0 ± 0 0.005
Renal insufficiency 5 (33.3%) 1 (50%) 0.199
Hepatitis B 11 (73.3%) 1 (50%) 0.496
HIV 1 (5.6%) 1 (50%) 0.047
Previous CVA 1 (5.6%) 0 0.732
Vegetation 15 (93.8%) 2 (100%) 0.716
Previous endocarditis 1 (5.6%) 0 0.732
GFR (mL/min/1.73 m2) 89.2 ± 43.2 82.5 ± 82.7 0.848
Creatinine (mg/dL) 1.9 ± 2.4 2.3 ± 2.1 0.855
Urea (mg/dL) 73.1 ± 60.4 73.5 ± 51.6 0.992
GGT (U/L) 88.4 ± 69.7 18.5 ± 0.7 0.186
ALT (U/L) 57.9 ± 43.6 10.5 ± 0.7 0.154
AST (U/L) 107.6 ± 121.3 258.5 ± 334.5 0.182







Staphylococcus aureus 6 (33.3%) 2 (100%)




Streptococcus species 4 (22.2%) 0
EuroSCORE II 6.89 ± 3.35 11.04 ± 3.35 0.036
BMI, body mass index; NYHA, New York Heart Association; HIV, human
immunodeficiency virus; CVA, cerebrovascular event; GFR, glomerular filtration
rate; GGT, gamma glutamyl transpeptidase; ALT, alanine aminotransferase; AST,
Aspartate transaminase.






Vegetation size (mm) 23.5 ± 8.7 35 ± 7.1 0.099
Bypass time (min) 130.4 ± 70.9 219.5 ± 120.9 0.126
Cross clamp time (min) 86.7 ± 44.4 136 ± 84.9 0.189
Operation duration (min) 219 ± 78 385 ± 148 0.016
Type of valve surgery 0.189
Mechanical prosthesis 11 (61.1%) 0
Biological prosthesis 6 (33.3%) 2 (100%)
Reconstruction 1 (5.6%) 0
Site of valve surgery 0.113
Aortic 4 (22.2%) 0
Mitral 2 (11.1%) 0
Tricuspid 7 (38.9%) 1 (50%)
Aortic and mitral 2 (11.1%) 0
Aortic and tricuspid 1 (5.6%) 0
Mitral and tricuspid 2 (11.1%) 0
Aortic, mitral and pulmonary 0 1 (50%)
Multivalve surgery 5 (27.8%) 1 (50%) 0.521
RBC (mL) 1267 ± 883 2900 ± 141 0.020
FFP (mL) 433 ± 441 200 ± 283 0.479
Platelets (mL) 267 ± 305 440 ± 622 0.503
Atrial fibrillation 11 (61.1%) 2 (100%) 0.521
AV-block 4 (23.5%) 1 (50%) 0.468
Permanent pacemaker 2 (11.8%) 0 1.000
Renal failure 5 (27.8%) 2 (100%) 0.111
Coagulation disorder 3 (17.6%) 1 (50%) 0.386
Reopening for bleeding 0 0
CVA 0 0
RBC, red blood cells; FFP, fresh frozen plasma; CVA, cerebrovascular accident.
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cal IE to vancomycin and rifampicin if the preoperative
antibiotic regime was ineffective post-operatively. Our
study data showed that patients receiving concentrations
of ≥10 mg/L vancomycin are more likely to become
afebrile and most of them have a normal white blood cell
count within 72 hours.
Staphylococci are prone to cause abscess formation
and early extracardiac organ manifestations. Fowler re-
ported that infection with Staphylococcus aureus was
associated with decreased survival compared to non –
Staphylococcus aureus infection [13]. This suggests sur-
gical treatment should be performed earlier when the
patient is in a less advanced state of systemic infection.
In the current study, two patients died 6 and 8 days after
surgery, whereas one patient died after 591 days. Thecause of death was severe sepsis in the first two cases and
sudden cardiac death in the third. An important finding
was that these patients also had significantly longer oper-
ation time and higher need for red blood cell transfusions
when compared to survivors. However, in most cases we
cannot influence the intraoperative course as it is primar-
ily determined by the nature of the disease.
The patients who died before post-operative day 30
suffered from severe bacteremia caused by Staphylococ-
cus aureus and when admitted to our hospital, were
mechanically ventilated and inotrope-dependent. A pre-
vious report from Van Duin has already demonstrated 1-
year mortality of 40% in patients with Staphylococcus
aureus bacteremia from any source with an attributable
mortality ranging between 8% and 16% [15]. Unfortu-
nately, we cannot provide additional information for the
patient who died after 591 days, because he was found
dead at home and no post mortem report was available.
Figure 2 Postoperative white cell count (WCC) course in 90-day survivors vs. 90-day non-survivors. There are no statistically significant
differences between the two groups (p = 1.000).
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significant predictor of early mortality. All patients who
died in the first 90 days after operation were in NYHA
class IV. This could be a strong argument to operate on
IVDUs with IE expeditiously, before the onset of acute
heart failure. A previous report also demonstrated simi-
lar results with patients arriving in cardiogenic shock in
which it was concluded that immediate surgery was the
only viable treatment option [16].
In this study there were no reoperations and no recur-
rent infection in spite of all patients being in the active
phase of endocarditis. In our opinion this demonstrates
our success with the radical approach in our institution.
However, radical surgery can compromise structures like
the cardiac conduction system; it resulted in the onset of
complete AV block postoperatively in two patients ne-
cessitating pacemaker implantation. However, we believe
that the deleterious effects of radical surgery are offset
by the benefits associated with the effective removal of
infected tissue.Figure 3 Postoperative CRP course in 90-day survivors vs. 90-day non
the two groups (p = 0.275).All of our patients were high frequency heroin abusers.
Heroin abuse is associated with bacteremia and endothe-
lial injury, simultaneously depressing respiratory function
and increasing pulmonary artery pressure significantly.
The same applies to cocaine and methamphetamine injec-
tions, which are associated with bacteremia, turbulent
flows in the heart and increased systemic afterload. These
combined effects can potentiate mitral and aortic valve in-
sufficiency and alter local blood flow in the valve region,
which may increase the risk of IE [17].
The surgeon who is considering placing a biopros-
thetic valve in an IVDU patient with IE has to make
challenging decisions regarding long-term durability
with the potential need for reoperation and anticipated
patient compliance with anticoagulation treatment.
More than the half of our patients received mechanical
prostheses primarily because they expressed reservations
about receiving a bioprosthesis because of durability
concerns and by persuading their surgeons that they
would be medically compliant and stop i.v. drug abuse.-survivors. There are no statistically significant differences between
Figure 4 Postoperative body temperature course in 90-day survivors vs. 90-day non-survivors. Postoperative body temperature was
significantly higher in the non-survivor group (p = 0.026) at all time points.
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between recipients of mechanical and bioprosthetic
valves. Bauernschmitt [19] reported encouraging results
with the use of mechanical prostheses in IE. The find-
ings of these two studies, in combination with those of
the current study, support the use of a mechanical pros-
thesis in IE.
In the current study, the operative risk associated with
multiple valve involvement did not exceed the risk
of single-valve disease, irrespective of affected valve
type, and was not accompanied by a significant increased
90-day mortality. Nevertheless, previously it has been
shown that multivalve endocarditis is a rare clinical en-
tity with a substantially elevated risk of morbidity and
mortality [20].
Some authors have identified coinfection with HIV
and the degree of immunosuppression as a risk factor of
mortality in IVDU patients with IE, particularly in pa-
tients with CD4 cell counts <200/mm3 [10,11,21]. In our
population, 10% of the patients were HIV infected. We
did not find any significant differences in the mortality
rate according to the HIV infection serostatus, which
may have been attributable to the low number of af-
fected patients.
Other studies have identified the presence of valvular
vegetation as a risk factor for complications [22-25]. Mi-
tral valve endocarditis with large staphylococcal vegeta-
tions in particular has been shown to be an independent
predictor of stroke [25], and this complication occurred
preoperatively in one patient in the current study. Gener-
ally, these vegetations are associated with a high concen-
tration of pathogens, are rarely responsive to antibiotic
treatment and represent a source of embolic events [12].
Moreover, in some studies it has been demonstrated that
vegetation size is predictive of outcome [22-24] but this
conclusion is not supported by another study which failed
to show an association between prognosis and vegetation
characteristics [12,26]. Transesophageal echocardiographyis effective in determining the location and size of vegeta-
tions, but in right-sided endocarditis, offers no advantages
over transthoracic imaging [26]. Nevertheless, transesoph-
ageal echocardiography remains a mandatory requirement
and represents the gold standard in IE evaluation.Limitations
The main limitation of this study is its retrospective
single-arm, non-randomized design involving a limited
number of patients from a single institution leading to
a low statistical power. Given the rare nature of the con-
dition, it was not possible to get a large number of pa-
tients and so, a prospective multi-centre long-term study
should be conducted to further characterize IE in IVDUs
in a larger patient sample. In spite of these limitations,
we were able to include consecutive patients and were
able to retrieve complete data records from the majority.
Theoretically, it would have been desirable to compare
outcomes of study patients with a medically treated con-
trol group although this was deemed to be ethically in-
feasible; all patients were deemed to be too sick for
further antibiotic therapy and thus were treated surgi-
cally. The onset of IE did not necessarily occur at the
time of the initiation antibiotic therapy. As most patients
were admitted by external hospitals, and many of them
were treated by their primary physicians, the exact onset
of the endocarditis could not be defined in each patient.Conclusions
Despite progress in antibiotic therapy and cardiac surgical
management, surgery of IE in active IVDUs remains de-
manding, because it entails high-risk surgical treatment
and targeted postoperative intensive care. An early diag-
nosis is a critical determinant of final outcome. In sum-
mary, the key to long-term success in IE is early and
radical surgical debridement of the infected tissue
followed by an aggressive postoperative antibiotic therapy.
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